Charles River Laboratories' Earnings Call Contradictions: NHP Supply Uncertainty and Clashing Margin Drivers

Date of Call: Aug 5, 2026

Guidance:

• Raised organic revenue growth rate by about 150 basis points.
• DSA segment projected to have low single-digit organic growth in second half of 2026.
• Expect margin expansion in 2027 from full impact of divestitures and Cambodia acquisition.

Business Commentary:

Revenue and EPS Guidance Raise:

• Charles River Laboratories raised its guidance for revenue and EPS, with an increase in organic revenue growth rate by about 150 basis points.
• The confidence in the raise is based on strong bookings in Q2 and positive trends in key lead indicators like net book-to-bill ratio, proposal volumes, and capture rates.

Modernization and Automation Initiatives:

• The company is focusing on modernizing labs with automation and digital systems to increase throughput and efficiency.
• These initiatives are aimed at improving speed and utilization across all segments and functions, with a deep dive planned during the investor day.

Non-Animal Methods (NAMs) Development:

• Charles River has established a scientific advisory board and hired a chief scientific officer to focus on NAMs development.
• The approach involves a mix of internal development, licensing, and partnerships to integrate NAMs into safety assessment workflows, enhancing insights for clients.

Defense and Security Agency (DSA) Business Trends:

• The DSA business is expected to show improvement, with a projection of low single-digit organic growth in the second half of the year.
• The deceleration in conversion rate is due to the timing from proposal to bookings and then to revenue generation, with some work still booked from last year.

Margin Outlook and Capacity Utilization:

• The company expects margin expansion in 2027 due to divestitures and the Cambodia acquisition but is not providing specific guidance for next year.
• In the second half of 2026, there will be a significant impact on margins, particularly in Q4, due to the timing of non-human primate costs on the revenue line.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed confidence in the raised guidance due to strong bookings and lead indicators, stating 'given the strength we're seeing in all the key lead indicators... we feel confident now that we're going to see better performance in the second half of the year.'

Q&A:

• Question from Ryan Halstead (RBC): My question is just on the guidance raise. If you could just offer some more color on the incremental visibility you have into the bookings that you now expect to convert in the second half.
  Response: Confidence is based on Q2 bookings; expects book-to-bill of one or greater for the rest of the year, which will largely impact 2027.

• Question from Ryan Halstead (RBC): My follow-up, just in terms of your modernization initiatives... wanted to ask specifically about NAMs.
  Response: Focus is on integrating NAMs into safety assessment workflows through a mix of internal development, licensing, and partnerships, with more details to come at investor day.

• Question from Todd Spencer (Charles River Laboratories): ...if you guys have seen any demand pickup from the DoD list and the Wooji on the no-fly list... any signs of early wins or conversations with those customers?
  Response: Discussions with clients in regulated space are limited, and Western clients are not yet taking their regulated work to China.

• Question from Todd Spencer (Charles River Laboratories): ...on the guide with the DSA business... implies there a decel in the conversion or burn rate... anything there...
  Response: The deceleration is due to timing from bookings to revenue generation; improvement is reflected with low single-digit organic growth projected for second half 2026.

• Question from Todd Spencer (Charles River Laboratories): ...how did the moving pieces leave you feeling on the margin set up into next year? Or I guess, how are you thinking about the margin potential for the business in Q4 and into 27?
  Response: Will not provide 2027 margin guidance yet; Q4 margin impact is significant due to NHP costs, but 2027 should see margin expansion from divestitures and acquisition tailwinds.

Contradiction Point 1

Nature and Timeline of NHP (Non-Human Primate) Supply Transition

Contradictory statements on the transition from external to internal NHP supply and its financial impact.

Todd Spencer (Charles River Laboratories) - Todd Spencer (Charles River Laboratories)

2026Q2: The company will not provide specific guidance for 2027 margins at this time due to many variables. The Q4 2026 run rate is significantly impacted (at least 500 basis points) by the timing of non-human primate (NHP) revenue recognition and should not be projected forward. - Glenn (CFO)

Given current safety capacity, utilization, and NHP costs, what is the margin potential for Q4 and into 2027? - Cassidy Van Epps (Jefferies)

2026Q1: Internal supply from K.F. Cambodia and Noveprim provides supply chain resilience and should improve financial performance; detailed guidance will be given in February 2027. - Glenn Coleman(CFO)

Contradiction Point 2

Strategic Integration and Growth Focus for NAMs (Non-Animal Methods)

Contradictory strategies on pursuing NAMs as a standalone business versus integrated into existing workflows.

Ryan Halstead (RBC) asks about earnings performance? - Ryan Halstead (RBC)

2026Q2: The strategy involves a broad mix of technologies and assays, primarily through internal development, followed by licensing and partnering. NAMs will be integrated into safety assessment workflows, not pursued as a standalone business. - Reporter (Charles River Laboratories)

Will modernization initiatives include collaborations/partnerships with biotech companies using innovative NAMs? - Elizabeth Anderson (Evercore ISI)

2026Q1: NAMs are integrated into the business and have accelerated in availability over the last decade... NAMs will evolve gradually alongside science and AI, replacing some animal models while remaining part of the revenue model in DSA and other divisions. - Birgit Girshick(CEO)

Contradiction Point 3

NHP Sourcing Cost Dynamics

Contradictory statements on the cause and timing of non-human primate (NHP) sourcing cost pressures.

Todd Spencer (Charles River Laboratories) - Todd Spencer (Charles River Laboratories)

2026Q2: The Q4 2026 run rate is significantly impacted (at least 500 basis points) by the timing of non-human primate (NHP) revenue recognition and should not be projected forward. - Glenn(CFO)

How will safety capacity, utilization rates, and NHP cost impacts affect margin potential in Q4 and into 2027? - Eric Coldwell (Robert W. Baird & Co. Incorporated)

2025Q4: Higher sourcing costs in Q4/Q1 were due to unexpectedly strong NHP study demand requiring purchases on the open market at higher prices. - Birgit Girshick(COO)

Contradiction Point 4

Demand Environment and Outlook

Inconsistent signals regarding the stability and linearity of client demand.

Ryan Halstead (RBC) - Ryan Halstead (RBC)

2026Q2: Strength in key lead indicators (net book-to-bill, proposal volumes, capture rate) supports better second-half performance. - Glenn(CFO)

Can you provide more details on the incremental visibility into bookings expected to convert in the second half and clarify whether this relates to mid-year bookings or prior years? - David Windley (Jefferies LLC)

2025Q4: Demand is improving... The environment feels more stable... The company is cautiously optimistic that demand trends will continue. - James Foster(CEO)

Contradiction Point 5

Margin Trajectory and Drivers

Disagreement on the primary drivers and timing for expected margin expansion.

Todd Spencer (Charles River Laboratories) - Todd Spencer (Charles River Laboratories)

2026Q2: The company will not provide specific guidance for 2027 margins... Margin expansion is expected from the full impact of divestitures and the Cambodia acquisition... - Glenn(CFO)

How do current safety capacity, utilization rates, and NHP cost impacts influence margin potential for Q4 and 2027? - Charles Rhyee (TD Cowen)

2025Q4: Sequential margin improvement will be driven by: 1) Cost savings and efficiency initiatives... 2) Lower NHP sourcing costs from the K.F. acquisition, particularly in the second half... - Michael Knell(CFO)